Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Breast Neoplasms 3Uterine Cervical Neoplasms 1Radiodermatitis 1Hyperthermia 1Eczema 1Dyspareunia 1Dermatitis 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 24Nivolumab 7Early Intervention, Educational 7Methods 6durvalumab 5aldesleukin 5Trastuzumab 5Paclitaxel 5Fulvestrant 5Carboplatin 5atezolizumab 4Surveys and Questionnaires 4Patient Navigation 4Docetaxel 4Cyclophosphamide 4Biopsy 4fludarabine 3Mass Screening 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Interleukin-2 3Gene Expression Profiling 3Fluorouracil 3Educational Status 3Bevacizumab 3tremelimumab 2spartalizumab 2sargramostim 2palbociclib 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Laser Therapy × Breast × Clear all
NCT03307044 2023-03-20

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

Ohio State University Comprehensive Cancer Center

Phase NA Completed
66 enrolled
BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Dyspareunia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡